Defects in insulin action in chronic heart failure

Doehner, Wolfram; Anker, Stefan D.; Coats, Andrew J.S.

doi:10.1046/j.1463-1326.2000.00058.x

Cited by 13 publications

(11 citation statements)

References 119 publications

(168 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanisms underlying this finding deserve closer scrutiny, as they shed light on a shifting paradigm of cardiovascular pathophysiology. Our understanding has shifted away from a mere hemodynamic disorder to a broader approach involving hormonal metabolic and immunologic derangements (14). In this context, increasing insulin resistance might be of pivotal importance.…”

Section: See Page 2267mentioning

confidence: 99%

“…Hyperinsulinemia may play an important part in the development of myocardial hypertrophy. This may also be regarded as an early aspect of the development of diabetes-associated cardiomyopathy that may ultimately yield chronic heart failure (CHF) (14). Obesity-related increases in fatty acids impair glucose utilization in a metabolic cycle that involves imbalanced substrates for energy metabolism (15).…”

Section: See Page 2267mentioning

confidence: 99%

“…Obesity-related increases in fatty acids impair glucose utilization in a metabolic cycle that involves imbalanced substrates for energy metabolism (15). The resulting insulin resistance accounts for a variety of effects including but not limited to increased oxidative stress, immune activation, tissue fibrosis, and impaired microvascular homeostasis, all of which contribute to the heart failure syndrome (14,16). Only recently, insulin resistance received increasing attention as part of the development and progression of CHF: it impacts on patients' symptomatic status and represents an independent marker of impaired survival (17).…”

Section: See Page 2267mentioning

confidence: 99%

See 2 more Smart Citations

Obesity and the Heart

Haehling

Doehner

Anker

2006

Journal of the American College of Cardiology

Self Cite

View full text Add to dashboard Cite

Section: See Page 2267mentioning

confidence: 99%

Section: See Page 2267mentioning

confidence: 99%

Section: See Page 2267mentioning

confidence: 99%

See 1 more Smart Citation

Obesity and the Heart

Haehling

Doehner

Anker

2006

Journal of the American College of Cardiology

Self Cite

View full text Add to dashboard Cite

“…However, insulin also drives increased sympathetic activation 22 and markedly elevates angiotensin II type 1 receptor expression, 23 causing sodium and water retention, vasoconstriction, increased afterload, and impaired peripheral blood flow 24 . Because of its crucial role in controlling the energetic state of the muscle and its function as a powerful anabolic factor, insulin has attracted increasing attention for its potential contribution to CV complications such as arteriosclerosis, hypertension, and left ventricular dysfunction 25 …”

Section: Insulin and Irmentioning

confidence: 99%

“…24 Because of its crucial role in controlling the energetic state of the muscle and its function as a powerful anabolic factor, insulin has attracted increasing attention for its potential contribution to CV complications such as arteriosclerosis, hypertension, and left ventricular dysfunction. 25…”

Section: Insulin and Irmentioning

confidence: 99%

Cardiovascular Implications of Thiazolidinedione Therapy

Lamb

King

2004

Progress Cardiovascular Nurs

View full text Add to dashboard Cite

The incidence of obesity and type 2 diabetes mellitus (DM2) in the United States has been increasing dramatically over the past 15 years, and is now at epidemic proportions. DM2 is the clinical manifestation of a long-term metabolic process that is initiated by cells' decreased sensitivity to the actions of insulin. Many outcome studies have identified DM2 as a strong and independent risk factor for the development of cardiovascular complications such as hypertension, arteriosclerosis, and heart failure. The goals of therapy in treating DM2 are to improve the long-term outlook for these patients. However, in selecting a therapeutic regimen for patients, clinicians should be aware that potentially severe adverse events may occur at a rate not previously identified in phase 3 studies. Certain therapies used to treat DM2, by effectively increasing the sensitivity of insulin, have also been reported to cause adverse effects, which can precipitate symptomatic heart failure. The purpose of this column is to discuss the therapeutic options available for treating patients with DM2, the potential pathophysiology of the adverse events of symptomatic heart failure, encouragement of use of the US Food and Drug Administration MedWatch program for reporting adverse events associated with medication therapy, and review of newer treatment guidelines for use of insulin-sensitizing agents in patients with chronic heart failure.

show abstract

Current Awareness

2000

Diabetes Metab. Res. Rev.

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 17 sections: 1 Books, Reviews & Symposia; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Prediction; 7 Prevention; 8 Intervention: a) General; b) Pharmacology; 9 Pathology: a) General; b) Cardiovascular; c) Neurological; d) Renal; 10 Endocrinology & Metabolism; 11 Nutrition; 12 Animal Studies; 13 Techniques. Within each section, articles are listed in alphabetical order with respect to author (11 Weeks journals ‐ Search completed at 6th Sept. 2000)

show abstract

Defects in insulin action in chronic heart failure

Cited by 13 publications

References 119 publications

Obesity and the Heart

Obesity and the Heart

Cardiovascular Implications of Thiazolidinedione Therapy

Current Awareness

Contact Info

Product

Resources

About